# Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)

> **NCT03954132** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 469 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Spiolto® Respimat®
- **DRUG:** Triple-Therapy (LAMA/LABA/ICS)

## Key facts

- **NCT ID:** NCT03954132
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-07
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 469 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03954132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03954132, "Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03954132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*